Fair value · Arbutus Biopharma Corp (ABUS) · updated 2026-11-18 · from 10-K FY2025
Arbutus Biopharma trades at $4.10. That price implies a P/E of 3.6× and 6.5% yearly EPS growth for a decade.
Cboe · delayed 15 min · as of 16:45 ET
Are those assumptions reasonable? Use ABUS’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- P/E
- 3.6×
- EPS growth
- 6.5%
price ÷ trailing EPS
per year for 10 years, discounted at 10%
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 16:45 ET.
Inputs come from the FY2025 10-K filed (accession 0001447028-26-000017); set your own on the sliders below. Research, not investment advice.
The filing behind these numbers
Arbutus Biopharma Corp- Revenue
- $14.1M
- Diluted EPS
- $-0.17
- Free cash flow
- $-39.6M
- operating cash flow − capital expenditure
- Diluted shares
- 191.6M
- weighted average
10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-23 · accession 0001447028-26-000017
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q3 FY2026 (filed 2026-11-10).
Open this filing on sec.govNeed ABUS data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.